The United States Patent and Trademark Office has granted US Patent entitled “Production of Salipro Particles”. The patent extends the company’s IP protection for its Salipro platform technologies into June 2042.

The newly granted US patent strengthens Salipro Biotech’s position as a global leader in membrane protein stabilization and expands its intellectual property estate across major pharmaceutical markets, it states. It protects a key method enabling the direct extraction and purification of functional membrane proteins, an essential capability for accessing previously inaccessible targets such as GPCRs, ion channels and SLC transporters.

“This new US patent represents an important milestone in the continued expansion of our global IP portfolio,” said Jens Frauenfeld, CEO of Salipro Biotech. “Our Salipro platform is already powering partnered drug discovery programs worldwide, and this patent further enhances the defensibility and value of our platform for our strategic partners.”